Bionovate Technologies Corp Stock Performance
| BIIO Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Bionovate Technologies are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Bionovate Technologies Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, Bionovate Technologies is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:100 | Dividend Date 2020-01-09 | Last Split Date 2020-01-09 |
1 | Stock Market Today Dow, Nasdaq Sink as AI Fears Resurface Live Updates - The Wall Street Journal | 11/20/2025 |
2 | Stock Market News From Jan. 21, 2026 Nasdaq Pops After Trump Backs Off Europe Tariffs - Barrons | 01/21/2026 |
Bionovate | Build AI portfolio with Bionovate Stock |
Bionovate Technologies Relative Risk vs. Return Landscape
If you would invest 0.01 in Bionovate Technologies Corp on November 15, 2025 and sell it today you would earn a total of 0.00 from holding Bionovate Technologies Corp or generate 0.0% return on investment over 90 days. Bionovate Technologies Corp is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Bionovate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bionovate Technologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bionovate Technologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bionovate Technologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bionovate Technologies generated a negative expected return over the last 90 days | |
| Bionovate Technologies has some characteristics of a very speculative penny stock | |
| Bionovate Technologies has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (106.54 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bionovate Technologies has a very weak financial position based on the latest SEC disclosures | |
| About 49.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Stock Market News From Jan. 21, 2026 Nasdaq Pops After Trump Backs Off Europe Tariffs - Barrons |
Bionovate Technologies Fundamentals Growth
Bionovate Stock prices reflect investors' perceptions of the future prospects and financial health of Bionovate Technologies, and Bionovate Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bionovate Stock performance.
| Current Valuation | 238.3 K | ||||
| Shares Outstanding | 7.75 M | ||||
| Price To Earning | 0.05 X | ||||
| EBITDA | (45.61 K) | ||||
| Net Income | (106.54 K) | ||||
| Total Debt | 237.38 K | ||||
| Book Value Per Share | (0.07) X | ||||
| Market Capitalization | 775 | ||||
| Retained Earnings | (2.8 M) | ||||
| Working Capital | (503.21 K) |
About Bionovate Technologies Performance
By examining Bionovate Technologies' fundamental ratios, stakeholders can obtain critical insights into Bionovate Technologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bionovate Technologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 134.86 | 171.39 | |
| Return On Tangible Assets | (47.13) | (49.49) | |
| Return On Capital Employed | 0.08 | 0.09 | |
| Return On Assets | (47.13) | (49.49) | |
| Return On Equity | 0.19 | 0.20 |
Things to note about Bionovate Technologies performance evaluation
Checking the ongoing alerts about Bionovate Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bionovate Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bionovate Technologies generated a negative expected return over the last 90 days | |
| Bionovate Technologies has some characteristics of a very speculative penny stock | |
| Bionovate Technologies has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (106.54 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bionovate Technologies has a very weak financial position based on the latest SEC disclosures | |
| About 49.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Stock Market News From Jan. 21, 2026 Nasdaq Pops After Trump Backs Off Europe Tariffs - Barrons |
- Analyzing Bionovate Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bionovate Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Bionovate Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bionovate Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bionovate Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bionovate Technologies' stock. These opinions can provide insight into Bionovate Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bionovate Technologies Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Will Health Care Equipment & Supplies sector continue expanding? Could Bionovate diversify its offerings? Factors like these will boost the valuation of Bionovate Technologies. Projected growth potential of Bionovate fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bionovate Technologies data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Bionovate Technologies's market price often diverges from its book value, the accounting figure shown on Bionovate's balance sheet. Smart investors calculate Bionovate Technologies' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Bionovate Technologies' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Bionovate Technologies' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bionovate Technologies should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bionovate Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.